The University of Texas MD Anderson Cancer Center today launched a pivotal, multi-year Strategy aimed at making the greatest impact on humanity in the institution’s work to end cancer. Developed with direct involvement from front-line cancer fighters and through ideas curated from gifted and talented faculty, MD Anderson’s new Strategy is anchored in its mission and grounded in its unwavering commitment to stakeholders in Texas, across...
Study defines small-cell lung cancer subtypes and distinct therapeutic vulnerabilities for each type
Researchers from The University of Texas MD Anderson Cancer Center have developed the first comprehensive framework to classify small-cell...
An all-star lineup of basketball greats, several of whom are courageous cancer survivors, will share their stories Feb. 4 at The University...
In an effort to address a major challenge when analyzing large single-cell RNA-sequencing datasets, researchers from The University of Texas MD Anderson Cancer Center have developed a new computational technique to accurately differentiate between data from cancer cells and the variety of normal cells found within tumor samples. The work was published today in Nature Biotechnology.
The new tool, dubbed CopyKAT (copy number karyotyping...
The University of Texas MD Anderson Cancer Center and UroGen Pharma Ltd. today announced a strategic three-year collaboration agreement to...
In a study to examine a Mediterranean diet in relation to prostate cancer progression in men on active surveillance, researchers from The...
The University of Texas MD Anderson Cancer Center and Xencor, Inc. today announced a strategic research collaboration and commercialization...
Researchers from The University of Texas MD Anderson Cancer Center who profiled more than 45,000 individual cells from patients with peritoneal...
Researchers at The University of Texas MD Anderson Cancer Center have discovered that a protein called NF-kappa B-inducing kinase (NIK) is...